BAUSCH HEALTH COS INC (BHC) Stock Price & Overview
NYSE:BHC • CA0717341071
Current stock price
The current stock price of BHC is 5.35 USD. Today BHC is down by -4.12%. In the past month the price decreased by -3.95%. In the past year, price increased by 0.38%.
BHC Key Statistics
- Market Cap
- 1.982B
- P/E
- 1.42
- Fwd P/E
- 1.23
- EPS (TTM)
- 3.77
- Dividend Yield
- N/A
BHC Stock Performance
BHC Stock Chart
BHC Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to BHC. When comparing the yearly performance of all stocks, BHC is a bad performer in the overall market: 81.73% of all stocks are doing better.
BHC Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BHC. BHC has a medium profitability rating, but doesn't score so well on its financial health evaluation.
BHC Earnings
On February 20, 2026 BHC reported an EPS of 1.1 and a revenue of 2.80B. The company missed EPS expectations (-13.87% surprise) and beat revenue expectations (2.23% surprise).
BHC Forecast & Estimates
9 analysts have analysed BHC and the average price target is 7.43 USD. This implies a price increase of 38.87% is expected in the next year compared to the current price of 5.35.
For the next year, analysts expect an EPS growth of 15.65% and a revenue growth 4.48% for BHC
BHC Groups
Sector & Classification
BHC Financial Highlights
Over the last trailing twelve months BHC reported a non-GAAP Earnings per Share(EPS) of 3.77.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 1.53% | ||
| ROA | 0.6% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BHC Ownership
BHC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.76 | 882.589B | ||
| JNJ | JOHNSON & JOHNSON | 20.87 | 585.389B | ||
| MRK | MERCK & CO. INC. | 23.36 | 298.838B | ||
| PFE | PFIZER INC | 9.48 | 161.094B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 121.374B | ||
| ZTS | ZOETIS INC | 16.66 | 49.786B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.4 | 28.018B | ||
| VTRS | VIATRIS INC | 5.36 | 15.475B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.94 | 11.475B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.619B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.372B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.599B | ||
| CORT | CORCEPT THERAPEUTICS INC | 51.43 | 4.52B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BHC
Company Profile
Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. The company is headquartered in Laval, Quebec and currently employs 20,300 full-time employees. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.
Company Info
IPO: 1994-09-20
BAUSCH HEALTH COS INC
2150 St. Elzear Blvd. West
Laval QUEBEC H7L 4A8 CA
CEO: Joseph C. Papa
Employees: 20700
Phone: 18003611448
BAUSCH HEALTH COS INC / BHC FAQ
What does BAUSCH HEALTH COS INC do?
Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. The company is headquartered in Laval, Quebec and currently employs 20,300 full-time employees. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.
What is the stock price of BAUSCH HEALTH COS INC today?
The current stock price of BHC is 5.35 USD. The price decreased by -4.12% in the last trading session.
Does BHC stock pay dividends?
BHC does not pay a dividend.
What is the ChartMill technical and fundamental rating of BHC stock?
BHC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the PE ratio for BHC stock?
The PE ratio for BAUSCH HEALTH COS INC (BHC) is 1.42. This is based on the reported non-GAAP earnings per share of 3.77 and the current share price of 5.35 USD.
What is BAUSCH HEALTH COS INC worth?
BAUSCH HEALTH COS INC (BHC) has a market capitalization of 1.98B USD. This makes BHC a Small Cap stock.
What is the Short Interest ratio of BAUSCH HEALTH COS INC (BHC) stock?
The outstanding short interest for BAUSCH HEALTH COS INC (BHC) is 2.18% of its float.